Why Liquid Cartilage™ is not available on the NHS

Liquid Cartilage™ — the UK commercial name for the injectable collagen scaffold ChondroFiller™ — is not available on the NHS anywhere in the United Kingdom, including Lincolnshire, for hip cartilage repair or any other joint. The barrier is regulatory, not clinical.

In England, NHS commissioning of new treatments depends on a positive technology appraisal from the National Institute for Health and Care Excellence (NICE). A NICE technology appraisal (TA) is a formal assessment of a treatment's clinical and cost effectiveness; without one, NHS trusts have no commissioning authority to fund the procedure as a routine option. NICE has not issued a technology appraisal for ChondroFiller in any joint indication — not the hip, not the knee — and no review timeline has been announced publicly. Near-term NHS availability cannot therefore be assumed.

It is worth being precise about what this means. ChondroFiller holds CE-marking as a Class III medical device, confirming it has satisfied the conformity requirements applied to higher-risk implantable products. That regulatory status is not in question. The absence of NHS funding reflects the separate and additional step of health technology assessment — a process that has simply not yet been initiated for this product. Patients considering Liquid Cartilage™ for hip cartilage damage are looking at a private pathway, and the rest of this article explains what that pathway involves.

What the NHS offers for hip cartilage damage

Standard NHS care for hip cartilage damage follows a stepwise ladder. A GP referral typically leads first to physiotherapy, weight management, and oral NSAIDs; if pain persists, a corticosteroid injection into the hip joint may be offered for short-term relief. When conservative measures fail and the joint has deteriorated to an advanced stage, the pathway ends at total hip replacement — currently carrying an average wait of around 27 weeks in England.

Biological cartilage repair does exist within the NHS, but not for the hip. Autologous chondrocyte implantation (ACI) was approved under NICE technology appraisal TA477 in October 2017 and is funded at a small number of specialist NHS centres. That approval is restricted to the knee; it does not extend to the hip joint.

For patients with focal hip cartilage damage — particularly younger or more active individuals who are not yet candidates for joint replacement — there is no NHS-funded scaffold or biological repair option anywhere in the UK. The NHS pathway offers either symptom management or, eventually, whole-joint surgery, with nothing in between that addresses the cartilage defect itself. Private routes exist precisely to fill that interval, and Liquid Cartilage™ is one of the few options currently available in the UK for doing so.

Which hip patients are suitable for Liquid Cartilage™

Not every hip cartilage problem is the right target for Liquid Cartilage™, and patient selection matters as much as the product itself.

ChondroFiller is best suited to a focal cartilage defect — a localised area where the cartilage has thinned to Grade III (significant thinning with surface disruption) or Grade IV (worn through to bone) in one part of the hip joint, while cartilage elsewhere in the joint remains largely intact. Typical candidates are younger or more active patients who want to preserve hip function and delay, or avoid, the need for total hip replacement. Common causes of this pattern of damage include hip impingement (FAI), sports injuries, and early degenerative change.

ChondroFiller is not appropriate for end-stage hip arthritis — bone-on-bone presentations where native cartilage has been lost across the joint surface. In those cases the scaffold has no viable tissue base to work with, and joint replacement is the more appropriate conversation.

Before any decision is made, MRI assessment is needed to characterise the defect's size, location, and the health of the surrounding joint. Lincolnshire Hip has open MRI available on-site, which allows imaging and clinical assessment to happen in the same setting before a treatment plan is agreed.

How the private pathway works at Lincolnshire Hip

For patients in Lincolnshire, the practical starting point is straightforward: Liquid Cartilage™ is available locally, in Grantham or Sleaford, with no need to travel to London.

A first appointment covers clinical history and imaging review; where MRI has not already been arranged, Lincolnshire Hip can organise this on-site before a treatment plan is agreed. The injection is not always carried out at the same visit — confirming the defect's character and the health of the surrounding hip joint comes first.

The procedure itself is an ultrasound-guided, outpatient injectable collagen scaffold treatment under local anaesthetic. There is no general anaesthetic, no overnight stay, and no surgical incision. ChondroFiller gel is placed precisely into the cartilage defect under real-time imaging guidance, then self-gels in situ to form a three-dimensional scaffold that the body's own cells can colonise and remodel.

After the injection, a protected loading period of four to six weeks allows the scaffold to stabilise and host progenitor cells to begin migrating into the matrix. Activity builds gradually from there, with MRI-visible repair tissue typically maturing over three to six months — though remodelling continues beyond that window.

Lincolnshire Hip is part of the MSK Doctors group and accepts self-referrals, meaning patients can book a hip assessment and discuss whether Liquid Cartilage™ is appropriate for their situation without waiting for a GP letter.

What ChondroFiller™ does inside the hip joint

ChondroFiller works through a process called acellular matrix-induced chondrogenesis. Once the Type I collagen gel sets inside the cartilage defect, it acts as a three-dimensional scaffold — a temporary structure that recruits the body's own progenitor cells from the surrounding synovium and subchondral bone. Those cells migrate into the matrix, differentiate, and produce fibrocartilage-like repair tissue. The collagen scaffold itself dissolves as the tissue matures. The injection does not directly regrow cartilage; it creates the conditions for the body's own repair to proceed where it otherwise would not.

The clinical data for hip applications shows meaningful functional improvement. In published hip series, modified Harris Hip Score — a 100-point functional outcome measure where the minimum clinically important difference is approximately 8–10 points — has improved by around 30 points following ChondroFiller treatment. A gain of that magnitude, roughly three times the threshold for a meaningful response, represents a substantial shift in pain and function for patients with focal hip cartilage damage. The hip-specific evidence base is more limited in volume than the broader knee literature, and that should inform expectations honestly; but the direction and scale of benefit in published hip data are encouraging.

On structural repair, MOCART imaging scores — a 0–100 MRI measure of how completely a defect has filled — have ranged from 81 to 84 across published series, indicating more than 80% defect filling at the treated site.

The recorded adverse event rate across ChondroFiller studies is approximately 0.06%, consistent with a strong short-term safety profile for an injectable collagen scaffold treatment.

Costs and insurance for Liquid Cartilage™ at Lincolnshire Hip

At Lincolnshire Hip, the self-pay guide cost is £2,995 per defect — a single outpatient appointment covering consultation, imaging review, the ChondroFiller scaffold, and the injection. No GP referral is needed to book an initial assessment.

For patients with private medical insurance, the procedure is billed under two recognised clinical codes: W3111 (cartilage regeneration with collagen scaffold) and W8500. These are the standard reference numbers insurers use when assessing and authorising a claim. In clinical practice, Bupa, Aviva, and WPA have approved claims under these codes — but cover depends entirely on the terms of each individual policy. The same codes can lead to full cover under one plan and no cover at all under another.

Written pre-authorisation from the insurer, obtained before treatment is booked, is essential. Verbal assurance is not a substitute, and cover should never be assumed simply because the billing codes are recognised. One distinction is worth stating plainly: a private insurer funding a private procedure is not NHS funding. The commissioning gap described earlier remains in place regardless of which insurer is involved — this is private healthcare accessed through a private route.